Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

January 31, 2010

Conditions
Acute Coronary SyndromeSleep Disorder
Interventions
DRUG

Eszopiclone

Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.

OTHER

Placebo

Subjects are given placebo for 3 consecutive nights

Trial Locations (1)

85723

Southern Arizona VA Health Care System, Tucson

All Listed Sponsors
collaborator

Sumitomo Pharma America, Inc.

INDUSTRY

collaborator

Southern Arizona VA Health Care System

FED

lead

University of Arizona

OTHER

NCT00822679 - Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome | Biotech Hunter | Biotech Hunter